Bertilimumab

Drug Profile

Bertilimumab

Alternative Names: Anti-eotaxin human monoclonal antibody - MedImmune; CAT-213; iCo-008

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Cambridge Antibody Technology; iCo Therapeutics; Immune Pharmaceuticals Inc
  • Class Antiallergics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Chemokine CCL11 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bullous pemphigoid; Crohn's disease; Ulcerative colitis
  • Phase I Allergic conjunctivitis; Asthma; Atopic dermatitis; Non-alcoholic steatohepatitis
  • Preclinical Wet age-related macular degeneration
  • Discontinued Allergic rhinitis; Ovarian cancer

Most Recent Events

  • 28 Sep 2017 Interim efficacy data from a phase II trial in Bullous pemphigoid released by Immune Pharmaceuticals
  • 04 Aug 2017 Immune Pharmaceuticals expects to complete a phase II trial in Bullous pemphigoid (Newly diagnosed) in Israel and USA in early 2018
  • 04 Aug 2017 Immune Pharmaceuticals expects to complete a phase II trial in Ulcerative colitis in Israel and Russia in the second quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top